Individuals Stopping Weight-Loss Medications Put On Pounds at a Quadrupled Rate Compared to Those on Conventional Diets

A recent study reveals that individuals who stop using blockbuster slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.

Research printed in a prominent medical journal shows that while obese individuals frequently drop a large proportion of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.

"People using these treatments should be informed of the potential of rapid rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.

Such speed of recovery means a return to starting mass in about a year and a half.

Analyzing Therapies

The research, which looked at dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.

Researchers emphasize that individuals who lose weight through dieting typically see a less rapid creep back—approximately 0.1 kg a month—once they finish.

Understanding the Fast Rebound

Nutrition scientists believe the way of the jabs is key to understanding the amplified rebound.

These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.

"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."

An Ongoing Disease?

The NHS suggest the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.

A number of clinicians argue that, given the likelihood of weight regain, the treatment is often long-term.

This perspective is reinforced by drug manufacturers, who note that the findings "underscore the persistent nature of obesity," akin to managing conditions like high blood pressure.

User Experiences

Individuals who have discontinued the medication describe a powerful return of appetite.

"It felt as if something flipping and I was suddenly ravenous," described a patient.

This challenge is compounded if patients have not adopted sustainable dietary or behavioural modifications during treatment.

Growing Interest

Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Adoption is higher among women than men.
• The 40s and 50s age group shows the highest usage rates.
• A large proportion obtain the medications through private healthcare rather than public health services.

In conclusion, researchers emphasize that while the jabs are powerful tools for shedding pounds, they are not a magic cure and long-term success likely depends on combined lifestyle support.